However, nicotinamide that has been investigated in a phase 3 clinical trial for skin-cancer prevention (our data provide a strong support to evaluate this preventive treatment for other cancer types) and exisulind itself have already demonstrated efficacy in clinical trials: these are direct convincing evidences in favour of the development of weak SIRT1 inhibitors. Here, SIRT1 is linked to cancer.